The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Open accessAbstract
PURPOSE: To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options. RESULTS: A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS: Patients undergoing neoadjuvant therapy should be managed by a multidisciplinary care team. Appropriate candidates for neoadjuvant therapy include patients with inflammatory breast cancer and those in whom residual disease may prompt a change in therapy. Neoadjuvant therapy can also be used to reduce the extent of local therapy or reduce delays in initiating therapy. Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic profiles. Patients with triple-negative breast cancer (TNBC) who have clinically node-positive and/or at least T1c disease should be offered an anthracycline- and taxane-containing regimen; those with cT1a or cT1bN0 TNBC should not routinely be offered neoadjuvant therapy. Carboplatin may be offered to patients with TNBC to increase pathologic complete response. There is currently insufficient evidence to support adding immune checkpoint inhibitors to standard chemotherapy. In patients with hormone receptor (HR)-positive (HR-positive), HER2-negative tumors, neoadjuvant chemotherapy can be used when a treatment decision can be made without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, hormone therapy can be used to downstage disease. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered neoadjuvant therapy in combination with anti-HER2-positive therapy. Patients with T1aN0 and T1bN0, HER2-positive disease should not be routinely offered neoadjuvant therapy. Additional information is available at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Mohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S., Canin, B., Cohen, H. J., Holmes, H. M., Hopkins, J. O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8687 · Cited by 1,479
Self-citationAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Wolmark, N., Wang, J., Mamounas, E., Bryant, J., & Fisher, B. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003469 · Cited by 1,299
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
Asselain, B., Barlow, W., Bartlett, J., Bergh, J., Bergsten-Nordström, E., Bliss, J., Boccardo, F., Boddington, C., Bogaerts, J., Bonadonna, G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30777-5 · Cited by 1,118
Self-citationvan der Hage, J. A., van de Velde, C. J. H., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., & Cooperating Investigators (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4224 · Cited by 1,107
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Self-citationSikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Self-citationSpring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 938
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Self-citationAdjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Self-citationKaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J.-U., Eiermann, W., Jackesz, R., Jonat, W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6187 · Cited by 725
Self-citationSymmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Self-citationNanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Self-citationTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 684
Self-citationSchnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Self-citationHurvitz, S. A., Martin, M., Symmans, W. F., Jung, K. H., Huang, C.-S., Thompson, A. M., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30716-7 · Cited by 534
Self-citationCost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Self-citationvan Ramshorst, M. S., van der Voort, A., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Dezentjé, V. O., Oving, I. M., Honkoop, A. H., Tick, L. W., van de Wouw, A. J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30570-9 · Cited by 452
Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., Hilfrich, J., Strumberg, D., Fasching, P. A., Kreienberg, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70397-7 · Cited by 451
Self-citationCarey, L. A., Berry, D. A., Cirrincione, C. T., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421
Self-citationUntch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
Self-citationSpring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1897 · Cited by 396
Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70411-x · Cited by 386
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
Chavez-MacGregor, M., Clarke, C. A., Lichtensztajn, D. Y., & Giordano, S. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3856 · Cited by 370
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.951s.11.2 · Cited by 348
Patel, M. I., Lopez, A. M., Blackstock, W., Reeder-Hayes, K., Moushey, E. A., Phillips, J., & Tap, W. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00642 · Cited by 338
Semiglazov, V. F., Semiglazov, V. V., Dashyan, G. A., Ziltsova, E. K., Ivanov, V. G., Bozhok, A. A., Melnikova, O. A., Paltuev, R. M., Kletzel, A., & Berstein, L. M. (2007) · Cancer · doi:10.1002/cncr.22789 · Cited by 333
von Minckwitz, G., Untch, M., Nüesch, E., Loibl, S., Kaufmann, M., Kümmel, S., Fasching, P. A., Eiermann, W., Blohmer, J.-U., Costa, S. D., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1228-x · Cited by 280
Self-citationTolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., Schneider, B. P., Shen, F., Fuhrman, K., Baltay, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00066 · Cited by 278
Self-citationvon Minckwitz, G., Kummel, S., Vogel, P., Hanusch, C., Eidtmann, H., Hilfrich, J., Gerber, B., Huober, J., Costa, S. D., Jackisch, C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn089 · Cited by 251
Self-citationPatient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Hurvitz, S. A., Martin, M., Jung, K. H., Huang, C.-S., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., Campone, M., Boileau, J.-F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00882 · Cited by 248
Self-citationImaging Neoadjuvant Therapy Response in Breast Cancer
Fowler, A. M., Mankoff, D. A., & Joe, B. N. (2017) · Radiology · doi:10.1148/radiol.2017170180 · Cited by 242
Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., Tomiak, E., Pritchard, K. I., Hamilton, A., & Piccart, M. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.135 · Cited by 224
von Minckwitz, G., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8303 · Cited by 223
Self-citationGianni, L., Baselga, J., Eiermann, W., Porta, V. G., Semiglazov, V., Lluch, A., Zambetti, M., Sabadell, D., Raab, G., Cussac, A. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2567 · Cited by 220
Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G.-Y., Di, G.-H., Zeng, X.-H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2965 · Cited by 213
Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero-Torres, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204
Carey, L. A., Metzger, R., Dees, E. C., Collichio, F., Sartor, C. I., Ollila, D. W., Klauber-DeMore, N., Halle, J., Sawyer, L., Moore, D. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji206 · Cited by 202
Self-citationPrat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., González Farré, B., Fernández, P. L., Galván, P., Chic, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30786-7 · Cited by 202
Golshan, M., Cirrincione, C. T., Sikov, W. M., Berry, D. A., Jasinski, S., Weisberg, T. F., Somlo, G., Hudis, C., Winer, E., & Ollila, D. W. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001417 · Cited by 196
Masuda, N., Sagara, Y., Kinoshita, T., Iwata, H., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70373-4 · Cited by 179
Locally Advanced and Inflammatory Breast Cancer
Chia, S., Swain, S. M., Byrd, D. R., & Mankoff, D. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.15.0243 · Cited by 179
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. A., Hutcheon, A. W., Coleman, R. E., Perren, T., Gallagher, C. J., Quigley, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.156 · Cited by 175
Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F. P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 173
Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G., Royce, M., McCall, L. M., Ewer, M. S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70502-3 · Cited by 170
Morgan, J., Wyld, L., Collins, K. A., & Reed, M. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004272.pub3 · Cited by 167
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto
Untch, M., Jackisch, C., Schneeweiß, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kümmel, S., Warm, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01842 · Cited by 165
Self-citationPandy, J. G. P., Balolong-Garcia, J. C., Cruz-Ordinario, M. V. B., & Que, F. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-6253-5 · Cited by 157
Denduluri, N., Chávez‐MacGregor, M., Telli, M. L., Eisen, A. F., Graff, S. L., Hassett, M. J., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8604 · Cited by 147
Self-citationBreast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Golshan, M. A., Loibl, S., Wong, S. M., Huober, J., O’Shaughnessy, J., Rugo, H. S., Wolmark, N., McKee, M. D., Maag, D., Sullivan, D. M., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2019.5410 · Cited by 143
Self-citationUntch, M., Fasching, P. A., Konecny, G. E., von Koch, F., Conrad, U., Fett, W., Kurzeder, C., Lück, H., Stickeler, E., Urbaczyk, H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq709 · Cited by 134
Self-citationPetrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2876-z · Cited by 133
Untch, M., von Minckwitz, G., Konecny, G. E., Conrad, U., Fett, W., Kurzeder, C., Lück, H., Stickeler, E., Urbaczyk, H., Liedtke, B., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq713 · Cited by 124
Self-citationEarl, H. M., Vallier, A.-L., Hiller, L., Fenwick, N., Young, J., Iddawela, M. Y., Abraham, J., Hughes‐Davies, L., Gounaris, I., McAdam, K., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70554-0 · Cited by 119
Checkpoint blockade in the treatment of breast cancer: current status and future directions
Wein, L., Luen, S. J., Savas, P. S., Salgado, R., & Loi, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0126-6 · Cited by 117
Killelea, B. K., Yang, V. Q., Wang, S., Hayse, B., Mougalian, S. S., Horowitz, N. R., Chagpar, A. B., Pusztai, L., & Lannin, D. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7801 · Cited by 108
Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P. G., Ballestrero, A., Dubsky, P. C., Lombard, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30334-1 · Cited by 107
Denduluri, N., Somerfield, M. R., Chávez‐MacGregor, M., Comander, A. H., Dayao, Z. R., Eisen, A. F., Freedman, R. A., Gopalakrishnan, R., Graff, S. L., Hassett, M. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02510 · Cited by 106
Self-citationHenry, N. L., Somerfield, M. R., Abramson, V. G., Allison, K. H., Anders, C. K., Chingos, D. T., Hurria, A., Openshaw, T. H., & Krop, I. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8609 · Cited by 98
Self-citationGolshan, M. A., Cirrincione, C., Sikov, W. M., Carey, L., Berry, D. A., Overmoyer, B. A., Henry, N. L., Somlo, G., Port, E. R., Burstein, H. J., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4006-6 · Cited by 93
Self-citationSikov, W. M., Berry, D., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Somlo, G., Port, E., Qamar, R., Sturtz, K. B., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-05 · Cited by 85
Self-citationACR Appropriateness Criteria ® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer
Slanetz, P. J., Moy, L. P., Baron, P. L., diFlorio‐Alexander, R. M., Green, E. D., Heller, S. L., Holbrook, A. I., Lee, S., Lewin, A. A., Lourenço, A. P., et al. (2017) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2017.08.037 · Cited by 83
Huober, J., Holmes, E. M., Baselga, J. M., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Láng, I., Smith, I., Boyle, F. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.038 · Cited by 82
Ellis, G. K., Barlow, W. E., Gralow, J. R., Hortobágyi, G. N., Russell, C. A., Royce, M., Perez, E. A., Lew, D. L., & Livingston, R. B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6543 · Cited by 81
Huober, J., Fasching, P. A., Hanusch, C. A., Rezai, M., Eidtmann, H., Kittel, K., Hilfrich, J., Schwedler, K., Blohmer, J., Tesch, H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.027 · Cited by 80
Self-citationvon Minckwitz, G., Rezai, M., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt410 · Cited by 75
Self-citationNagayama, A., Hayashida, T., Jinno, H., Takahashi, M., Seki, T., Matsumoto, A., Murata, T., Ashrafian, H., Athanasiou, T., Okabayashi, K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju203 · Cited by 69
Untch, M., von Minckwitz, G., Gerber, B., Schem, C., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Hanusch, C. A., Huober, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.9175 · Cited by 66
Self-citationManagement of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach
Sheng, J. Y.-S., Santa-Maria, C. A., Mangini, N. S., Norman, H., Couzi, R. J., Nunes, R., Wilkinson, M. J., Visvanathan, K., Connolly, R. M., Torres, E. T. R., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00364 · Cited by 66
Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer
Beaver, K., WILLIAMSON, S. L., & Briggs, J. (2015) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2015.06.001 · Cited by 65
Kim, H. J., Noh, W. C., Lee, E. S., Jung, Y. S., Kim, L. S., Han, W., Nam, S. J., Gong, G. Y., Kim, H. J., & Ahn, S. H. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01288-5 · Cited by 65
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834120aa · Cited by 63
Warner, E. T., Ballman, K. V., Strand, C. A., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3918-5 · Cited by 59
Bagegni, N. A., Yu, T., & Ademuyiwa, F. O. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222358 · Cited by 55
Race, response to chemotherapy, and outcome within clinical breast cancer subtypes
Tichy, J. R., Deal, A. M., Anders, C. K., Reeder-Hayes, K. E., & Carey, L. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3350-2 · Cited by 54
Self-citationChávez‐MacGregor, M., Litton, J. K., Chen, H., Giordano, S. H., Hudis, C. A., Wolff, A. C., Valero, V., Hortobágyi, G. N., Bondy, M. L., & Gonzalez-Angulo, A. M. (2010) · Cancer · doi:10.1002/cncr.25296 · Cited by 53
Hicks, M. J., Macrae, E. R., Abdel‐Rasoul, M., Layman, R. M., Friedman, S., Querry, J., Lustberg, M. B., Ramaswamy, B., Mrózek, E., Shapiro, C. L., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0334 · Cited by 52
Valachis, A., Nearchou, A. D., Lind, P., & Mauri, D. N. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2189-z · Cited by 51
Garrison, L. P., Babigumira, J. B., Tournier, C., Goertz, H., Lubinga, S. J., & Perez, E. A. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.014 · Cited by 48
Vriens, B. E. P. J., Aarts, M. J. B., de Vries, B., van Gastel, S. M., Wals, J., Smilde, T. J., van Warmerdam, L. J. C., de Boer, M., van Spronsen, D. J., Borm, G. F., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.012 · Cited by 43
Chen, S., Yu, L., Feng, Z., & Wang, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6132-0 · Cited by 41
Clavarezza, M., Puntoni, M., Gennari, A., Paleari, L., Provinciali, N., D’Amico, M., & DeCensi, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1881 · Cited by 39
Platinum-based chemotherapy in triple-negative breast cancer
Guan, X., Ma, F., Fan, Y., Zhu, W., Hong, R., & Xu, B. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000260 · Cited by 35
Bria, E., Carbognin, L., Furlanetto, J., Pilotto, S., Bonomi, M., Guarneri, V., Vicentini, C., Brunelli, M., Nortilli, R., Pellini, F., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.001 · Cited by 26
Arun, B. K., Dhinghra, K., Valero, V., Kau, S., Broglio, K. R., Booser, D. J., Guerra, L., Yin, G., Walters, R. S., Şahin, A. A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0134 · Cited by 26
The association of socioeconomic status with receipt of neoadjuvant chemotherapy
Neuner, J. M., Kong, A. L., Blaes, A. H., Riley, D. J., Chrischilles, E. A., Smallwood, A. J., Lizarraga, I. M., & Schroeder, M. C. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4954-0 · Cited by 23
Ding, Y., Ding, K., Yang, H., He, X., Mo, W., & Ding, X. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234058 · Cited by 23
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer
Nakashoji, A., Hayashida, T., Yokoe, T., Maeda, H., Toyota, T., Kikuchi, M., Watanuki, R., Nagayama, A., Seki, T., Takahashi, M., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.009 · Cited by 21
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic
Spring, L. M., Specht, M. C., Jimenez, R., Isakoff, S. J., Wang, G. X., Ly, A., Shin, J. A., Bardia, A., & Moy, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc2002422 · Cited by 19
Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer
Pastoriza, J. M., Karagiannis, G. S., Lin, J., Lanjewar, S. D., Entenberg, D. R., Condeelis, J. S., Sparano, J. A., Xue, X., Rohan, T. E., & Oktay, M. H. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9932-8 · Cited by 18
Vriens, B. E. P. J., Vriens, I. J. H., Aarts, M. J. B., van Gastel, S. M., van den Berkmortel, F. W. P. J., Smilde, T. J., van Warmerdam, L. J. C., van Spronsen, D. J., Peer, P. G. M., de Boer, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4364-8 · Cited by 17
Villarreal-Garza, C. M., Soto‐Pérez‐de‐Celis, E., Sifuentes, E., Ruano, S., Baez-Revueltas, B., Lara-Medina, F. U., Arce-Salinas, C., Alvarado‐Miranda, A., Chávarri-Guerra, Y., Caro-Sánchez, C. H. S., et al. (2015) · The Breast · doi:10.1016/j.breast.2015.01.011 · Cited by 11
Imputing estrogen receptor (ER) status in a population‐based cancer registry: a sensitivity analysis
Andridge, R., Noone, A., & Howlader, N. (2016) · Statistics in Medicine · doi:10.1002/sim.7193 · Cited by 8
Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer
Howard-McNatt, M. M., Lawrence, J. A., Melin, S. A., et al. (2013) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2013.01.009 · Cited by 7
Cited by
Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,286
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,008
Self-citationDeep learning in histopathology: the path to the clinic
van der Laak, J., Litjens, G., & Ciompi, F. (2021) · Nature Medicine · doi:10.1038/s41591-021-01343-4 · Cited by 902
Advances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
The emerging role of photoacoustic imaging in clinical oncology
Lin, L., & Wang, L. V. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00615-3 · Cited by 469
Metadata
- Authors
- Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., Regan, M. M., Spears, P. A., Sudheendra, P. K., Symmans, W. F., Yung, R. L., Harvey, B. E., & Hershman, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-05-01
- Volume
- 39
- Issue
- 13
- Pages
- 1485-1505
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3122861570
- Cited by
- 1,040
- References
- 119
- FWCI
- 50.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.